Noradrenergic drugs for levodopa-induced dyskinesia.


Dyskinesia frequently mars the long-term therapeutic response to levodopa (LD) in Parkinson's disease (PD). New treatment strategies for levodopa-induced dyskinesia (LID) currently being investigated include some that target the nondopaminergic pathways. Indeed, LID in parkinsonism can be modulated by drugs acting on different neurotransmitters including… (More)


Cite this paper

@article{Colosimo2003NoradrenergicDF, title={Noradrenergic drugs for levodopa-induced dyskinesia.}, author={C. Colosimo and Alessandra Craus}, journal={Clinical neuropharmacology}, year={2003}, volume={26 6}, pages={299-305} }